6 completed, 2 terminated, 1 withdrawn. 6 Phase 2, 3 Phase 1, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 4, Terminated 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 3 |
| Not applicable | 1 | Terminated 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Modified FOLFOX6: new trials by email Literature Review of Modified FOLFOX6 trials Research Report on Modified FOLFOX6
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC NIS793, Bevacizumab, Modified FOLFOX6 - Metastatic Colorectal Cancer | Phase 2 | Terminated | Novartis Pharmaceuticals | 204 | 2021-11-15 | 2025-03-26 |
| Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers Gevokizumab, Bevacizumab, Modified FOLFOX6 - Colorectal Cancer, Gastroesophageal Cancer | Phase 1 | Completed | Novartis Pharmaceuticals | 167 | 2019-05-22 | 2026-04-01 |
| A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer Bemarituzumab, Placebo, Modified FOLFOX6 - Gastric Cancer | Phase 2 | Completed | Five Prime Therapeutics, Inc. | 155 | 2018-09-14 | 2024-02-28 |
| A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer Bemarituzumab, Modified FOLFOX6 - Gastrointestinal Cancer, Gastrointestinal Cancer Metastatic | Phase 1 | Completed | Five Prime Therapeutics, Inc. | 12 | 2017-11-30 | 2024-02-28 |
| Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach Modified FOLFOX6, Docetaxel/Capecitabine, Cisplatin/Irinotecan - Esophageal Cancer, Gastric Cancer | Not applicable | Terminated | Georgetown University | 13 | 2015-02-01 | 2018-09-06 |
| Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases Modified FOLFOX6, Aflibercept, Surgery - Colorectal Cancer Metastatic, Liver Metastases | Phase 2 / Phase 3 | Withdrawn | European Organisation for Research and Treatment of Cancer - EORTC | 2012-12-01 | 2017-05-09 | |
| Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) Modified FOLFOX6, Conatumumab, Ganitumab - Advanced Solid Tumors, Carcinoid | Phase 2 | Completed | Amgen | 12 | 2011-03-03 | 2021-02-21 |
| Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer Placebo, AMG 655, Modified FOLFOX6 - Metastatic Colorectal Cancer, Colon Cancer | Phase 1 / Phase 2 | Completed | Amgen | 202 | 2007-10-01 | 2014-04-25 |
| Perioperative mFOLFOX-6 in Locally Advanced Gastric Cancer MODIFIED FOLFOX6 - Advanced Gastric Cancer | Phase 2 | Completed | Seoul National University Hospital | 52 | 2004-06-01 | 2025-04-17 |
Colorectal Neoplasms (5) · Stomach Neoplasms (3) · Carcinoid Tumor (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Esophageal Neoplasms (1) · Gastrointestinal Neoplasms (1) · Lymphoma (1) · Neoplasm Metastasis (1) · Rectal Neoplasms (1) · Sarcoma (1)
Amgen (2) · Five Prime Therapeutics, Inc. (2) · Novartis Pharmaceuticals (2) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Georgetown University (1) · Seoul National University Hospital (1)
United States (7) · South Korea (4) · Spain (4) · Australia (3) · Belgium (3) · Germany (3) · Italy (3) · Japan (3) · Taiwan (3) · United Kingdom (3) · Canada (2) · Czechia (2) · France (2) · Israel (2) · Poland (2)
Bernard Nordlinger, Pr. (1) · John Marshall, MD (1) · Seock-Ah Im, MD, PhD (1)
PMID 32965540, PMID 36244398, PMID 38308771
2017 (1), 2018 (1)